Clopidogrel
Clopidogrel
Additional Information

Clopidogrel Technical Review

On March 12, 2010, the US Food and Drug Administration added a new boxed warning to the antiblood clotting agent Plavix® (clopidogrel) advising that the drug may be less effective in those who cannot metabolize it into its active form by the liver enzyme CYP2C19.  The FDA indicated that tests are available to assess a patient’s CYP2C19 metabolizer status.  LabCorp has offered Clopidogrel CYP2C19 Genotyping since April 2009. 

To learn more about this test, please click on the link listed in Additional Information or view the Clopidogrel CYP2C19 Genotyping test details.